Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Pediatric and Young Adult R/R Mature B-cell NHL
NCT02703272Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2016
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of ibrutinib in mature B-cell non-Hodgkin lymphoma, sponsored by Janssen Pharmaceutical. Started Jul 2016; status: terminated.
02
Drugs
ibrutinib
03
Conditions
mature B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02703272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02703272.